Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Dow
Baxter
AstraZeneca
Medtronic

Last Updated: May 22, 2022

Dacomitinib - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

What are the generic sources for dacomitinib and what is the scope of patent protection?

Dacomitinib is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dacomitinib has fifty-five patent family members in forty-five countries.

Two suppliers are listed for this compound.

Summary for dacomitinib
International Patents:55
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 77
Clinical Trials: 34
Patent Applications: 1,909
What excipients (inactive ingredients) are in dacomitinib?dacomitinib excipients list
DailyMed Link:dacomitinib at DailyMed
Recent Clinical Trials for dacomitinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Shanghai Chest HospitalPhase 1/Phase 2
Genome Institute of SingaporePhase 2
Cancer Science Institute of SingaporePhase 2

See all dacomitinib clinical trials

US Patents and Regulatory Information for dacomitinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer VIZIMPRO dacomitinib TABLET;ORAL 211288-003 Sep 27, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Pfizer VIZIMPRO dacomitinib TABLET;ORAL 211288-002 Sep 27, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Pfizer VIZIMPRO dacomitinib TABLET;ORAL 211288-003 Sep 27, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Pfizer VIZIMPRO dacomitinib TABLET;ORAL 211288-002 Sep 27, 2018 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for dacomitinib

Country Patent Number Title Estimated Expiration
Ukraine 85706 4-ФЕНІЛАМІНОХІНАЗОЛІН-6-ІЛАМІДИ[4-ФЕНИЛАМИНОХИНАЗОЛИН-6-ИЛАМИДЫ (4-PHENYLAMINOQUINAZOLIN-6-YL AMIDES) See Plans and Pricing
China 1972688 4-phenylamino-quinazolin-6-yl-amides See Plans and Pricing
Costa Rica 8727 4-FENILAMINO-QUINAZOLIN-6-IL-AMIDAS See Plans and Pricing
Eurasian Patent Organization 200601849 4-ФЕНИЛАМИНОХИНАЗОЛИН-6-ИЛ-АМИДЫ See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for dacomitinib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1746999 350 16-2019 Slovakia See Plans and Pricing PRODUCT NAME: DAKOMITINIB; REGISTRATION NO/DATE: EU/1/19/1354 20190404
1746999 1990044-8 Sweden See Plans and Pricing PRODUCT NAME: DACOMITINIB OR APHARMACEUTICAL ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/19/1354 20190404
1746999 LUC00127 Luxembourg See Plans and Pricing PRODUCT NAME: DACOMITINIB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZIMPRO ); AUTHORISATION NUMBER AND DATE: EU/1/19/1354 20190404
1746999 19C1052 France See Plans and Pricing PRODUCT NAME: DACOMITINIB, Y COMPRIS UN DE SES HYDRATES, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/19/1354 20190404
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Johnson and Johnson
Express Scripts
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.